Cellmid 2018 Annual Report 39
Revenue from continuing operations
Loss before income tax includes the following specific expenses:
Accounting Policy
The income tax expense or benefit for the period is the tax payable on the current period’s taxable income based on the
national income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to
temporary differences, unused tax losses and adjustments recognised for prior periods where applicable. The Group is
tax consolidated in Australia.
Deferred tax assets relating to temporary differences and unused tax losses are recognised only to the extent that it is probable
that future taxable profit will be available against which the benefits of the deferred tax asset can be utilised.
Current tax assets and liabilities are offset only where a legally enforceable right of set off exists and it is intended that the
net settlement or simultaneous realisation and settlement of the respective asset and liability will occur.
2018 2017
$ $
Sales revenue:
Consumer health 5,647,930 4,496,338
Other revenue:
Interest received 33,599 56,956
Licence fees and royalties 64,252 147,520
Other revenue 14,388 21,792
112,239 226,268
Total revenue 5,760,169 4,722,606
Other income:
Government grants 1,056,963 831,408
Gain on foreign exchange 16,972 -
Other income 820 6,107
Total other income 1,074,755 837,515
2018 2017
$ $
Manufacturing sales expense (2,169,844) (2,118,717)
Finance costs (473,274) (291,173)
Defined contribution superannuation expense (240,030) (188,938)
Loss on foreign exchange - (61,636)
Rental expense on leased premises (281,468) (223,350)
Depreciation and amortisation expense (187,538) (168,523)
Research and development expense (598,480) (599,605)